The raised guidance and solid beat across both top and bottom lines suggest momentum in plasma and MedSurg segments. Watch for continued execution on NexSys adoption and any commentary on hospital capital spending trends in the upcoming conference call.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 5 $124.11entry
- T+1 · 11d ago −3.37%α −3.68% · $119.93
- T+5 · 5d ago −1.13%α −4.42% · $122.71
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
The company raised its full-year revenue guidance to $1.415B-$1.435B from $1.395B-$1.425B, reflecting confidence in continued growth.
Key Financial Metrics
Key Facts
- Q2 FY2027 revenue $353.4M vs consensus $345.1M (beat by 2.4%)
- Revenue grew 6.5% YoY from $331.8M in Q2 FY2026
- Full-year FY2027 revenue guidance raised to $1.415B-$1.435B from prior $1.395B-$1.425B
- Full-year FY2027 EPS guidance raised to $5.25-$5.45 from prior $5.10-$5.30
- Plasma revenue increased 8% YoY to $200.5M; MedSurg revenue up 5% YoY to $152.9M
- Operating cash flow was $62.1M; free cash flow was $48.5M
Financial Impact
Revenue beat of $8.3M (2.4%) and EPS beat of $0.02 (1.6%); guidance raised by $20M at midpoint for revenue and $0.15 for EPS
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Plasma | $200.5M | +8.0% |
| MedSurg | $152.9M | +5.0% |
Risk Factors
- Plasma collection volumes could moderate if donor compensation dynamics shift
- MedSurg growth may slow if hospital budgets tighten
- Currency headwinds could impact reported revenue in subsequent quarters
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302930182 |
Track record
14 reports on HAE
2 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +2.44% at T+5 after the Oct 20, 2026 report. 2 of 3 went positive at some point.
Filters
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $122.71 Now $121.34 −1.12% settles Nov 19
- Nov 5, 202611d ago 8-K Bullish 6/10 No price data
- Nov 5, 202611d ago Press Release Bullish 5/10 Viewing Entry $124.11 to $122.71 Now $121.34 −2.23% ▼ −1.13% −4.42% vs SPY
- Oct 20, 202627d ago Institutional Cluster Bullish 4/10 Entry $117.11 to $119.97 Now $121.34 +3.61% ▲ +2.44% +2.89% vs SPY
- Oct 19, 202628d ago Press Release Bullish 7/10 Entry $118.21 to $119.97 Now $121.34 +2.65% ▲ +1.49% +1.41% vs SPY
- Oct 12, 20265w ago Institutional Cluster Bullish 4/10 Entry $122.06 to $118.73 Now $121.34 −0.59% ▼ −2.73% −1.23% vs SPY
- Oct 8, 20265w ago 8-K Neutral 4/10 Entry $119.47 to $121.29 Now $121.34 +1.57% ▲ +1.52% +1.80% vs SPY
- Sep 30, 20266w ago Press Release Neutral 1/10 Entry $104.37 to $119.47 Now $121.34 +16.26% ▲ +14.47% +13.17% vs SPY
- Sep 30, 20266w ago Court Ruling Neutral 3/10 Entry $104.37 to $119.47 Now $121.34 +16.26% ▲ +14.47% +13.17% vs SPY
- Aug 18, 202612w ago 8-K Neutral 3/10 Entry $104.65 to $108.32 Now $121.34 +15.95% ▲ +3.51% +3.71% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers